Bayer Ag · XETR:BAYN
Bayer — Investor Day (March 2021)
31 slides from Bayer's investor day presentation, Mar 10, 2021
Slide 1: Paving the Way for our Future in Science-based Innovation
Paving the Way for our Future in Science-based Innovation /////////// Capital Markets Day March 10-11, 2021 Christian Rommel Head of R&D Pharmaceuticals 1
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac
Slide 3: Joining Bayer as the new Head of Pharma R&D
1 Overview Joining Bayer as the new Head of Pharma R&D Results of Personal Due Dilligence for R&D Areas of Strength Areas to Strengthen • Excellence in small molecule drug discovery • Historical focus and dependence on small molecules • Committed to areas of high unmet need • Over reliance on intern
Slide 4: Strong Track Record of Pharma Innovation to Deliver Differentiated Drugs
1 Overview Strong Track Record of Pharma Innovation to Deliver Differentiated Drugs Verquvo1 First-in-class treatment for heart failure Nubeqa2 AR antagonist with differentiated side-effect profile for the treatment of prostate cancer Vitrakvi NTRK gene fusion cancer treatment Adempas sGC modulator
Slide 5: Maximizing Opportunities Created through Science to Deliver Solutions that Matter to Patients
1 Overview Maximizing Opportunities Created through Science to Deliver Solutions that Matter to Patients Science-based, patient-centric and evidence-based Deep understanding of disease biology and diverse range of modalities Harnessing business opportunities Addressing unmet medical need to the bene
Slide 6: We Focus on Diseases with High Unmet Need and apply a Broad Range of Modalities
2 R&D Areas We Focus on Diseases with High Unmet Need and apply a Broad Range of Modalities Main Disease Areas Cardiovascular Endocrinology, Adjacencies: Oncology Metabolism & Ophthalmology, Diseases Reproductive Health Rare Diseases Small Antibodies Radio- Cell RNA Gene Digital Molecules therapies
Slide 7: Highlighting Late-/mid-stage Pipeline Opportunities and Scientifically Appealing Early R&D Assets
3 R&D Highlights Highlighting Late-/mid-stage Pipeline Opportunities and Scientifically Appealing Early R&D Assets Late-/mid-stage Opportunities1 ScientificallyAppealing Early Assets1 Finerenone Precision Molecular Oncology • CKD in T2 Diabetes Patients • EGFRex20 inhibitor • Heart Failure • ATR inh
Slide 8: CKD in T2D Creates a High Disease Burden for Patients and Healthcare Systems
4 Cardiovascular Diseases CKD in T2D Creates a High Disease Burden for Patients and Healthcare Systems, yet it is Critically Underdiagnosed <50% 417 million people with T2D, expected to reach >600 million by 2045 >120M of patients with CKD in T2D are currently diagnosed People with CKD in T2D* #1 3x
Slide 9: Finerenone Targets a Key Driver of CKD Progression in Patients with Type 2 Diabetes
4 Cardiovascular Diseases Finerenone Targets a Key Driver of CKD Progression in Patients with Type 2 Diabetes Drivers for CKD Progression Treatment Approach1 • Currently no treatment • Finerenone is targeting overactivation of the specifically addressing mineralocorticoid receptor, thus potentially
Slide 10: FIDELIO and FIGARO are the Largest CKD Trial Program in Patients With T2D
4 Cardiovascular Diseases FIDELIO and FIGARO are the Largest CKD Trial Program in Patients With T2D With More Than 13,000 Patients Enrolled Finerenone 10 mg od (eGFR 25–<60 ml/min/1.73 m2) Run-in Screening Finerenone 20 mg od (eGFR ≥60 ml/min/1.73 m2) R period period Placebo 1 2 Primary Composite en
Slide 11: Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in Patients with CKD and Type 2 Diabetes
4 Cardiovascular Diseases Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in Patients with CKD and Type 2 Diabetes FIDELIO Primary composite outcome Finerenone in FIDELIO-DKD (Kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal cause
Slide 12: Expanding the Clinical Program for Finerenone into Heart Failure
4 Cardiovascular Diseases Expanding the Clinical Program for Finerenone into Heart Failure FINEARTS-HF Phase III Trial in Patients with Heart Failure and LVEF ≥40% Finerenone 10, 20 and 40 mg • >50% of HF patients suffer from HF with LVEF ≥40% based on eGFR • High unment medical need - limited treat
Slide 13: Significant Progress has been Achieved in Anti-coagulation Therapy but Medical Need Still Exists
4 Cardiovascular Diseases Significant Progress has been Achieved in Anti-coagulation Therapy but Medical Need Still Exists NOACs Vitamin K Direct Direct FXa Heparin Antagonists LMWH Thrombin Inhibitors (VKA) Inhibitors • Heparin and VKAs were the only anticoagulants available for most of the 20th ce
Slide 14: Hereditary Factor XI Deficiency is Associated with Lower Risk for Cardiovascular and VTE Events
4 Cardiovascular Diseases Hereditary Factor XI Deficiency is Associated with Lower Risk for Cardiovascular and Venous Thromboembolic Events Rate of Venous Thromboembolism Rate of Cardiovascular Events depending on FXI Level depending on FXI Level Factor XI >50% Rate of venous thromboembolism Rate of
Slide 15: Bayer Has a Broad and Diverse Factor XI(a) Portfolio
4 Cardiovascular Diseases Bayer Has a Broad and Diverse Factor XI(a) Portfolio Asset Mode of Action Comprehensive Phase IIb Program Antisense technology prevents FXI expression • RE-THINc ESRD FXI-Antisense1 (IONIS-LICA) Reduction of thrombotic events in end- stage renal disease patients on Hepato
Slide 16: FOXTROT Phase II Data Confirm Proof of Concept for Osocimab
4 Cardiovascular Diseases FOXTROT Phase II Data Confirm Proof of Concept for Osocimab Factor XIa Inhibition by Osocimab Delivers Positive Clinical Results Primary VTE Outcome % 40 30 20 • Single doses of osocimab vs. enoxaparin and apixaban for thromboprophylaxis in knee arthroplasty 10 0 • Postoper
Slide 17: High Unmet Medical Need for Non-hormonal Treatment of Vasomotor Symptoms in Menopausal Women
5 Women´s Health High Unmet Medical Need for Non-hormonal Treatment of Vasomotor Symptoms in Menopausal Women Typical Vasomotor Symptoms During Menopause • Elinzanetant (KaNDy NT-814) is a first-in-class, non- hormonal, once-daily, oral neurokinin-1,3 receptor antagonist • May reduce the hyperactivi
Slide 18: Elinzanetant Demonstrates Significant and Rapid Reduction in Vasomotor Symptoms
5 Women´s Health Elinzanetant Demonstrates Significant and Rapid Reduction in Vasomotor Symptoms in Menopausal Women Reduction in moderate/severe VMS per day from baseline • Phase IIb dose finding trial (SWITCH-1) including Week 4 Week 12 199 women • Primary endpoint results: o Rapid and highly sign
Slide 19: Eliapixant, a P2X3 Receptor Antagonist with Multi-indication Potential
6 P2X3 Rec. Antagonist Eliapixant, a P2X3 Receptor Antagonist with Multi-indication Potential • P2X3 is an ATP-activated ion channel expressed mainly in the peripheral nervous system • P2X3 is a major regulator of afferent nerve fiber signaling and a prominent mediator of pain • Inhibition of P2X3 c
Slide 20: Eliapixant Demonstrated Proof of Concept in Refractory and/or Unexplained Chronic Cough
6 P2X3 Rec. Antagonist Eliapixant Demonstrated Proof of Concept in Refractory and/or Unexplained Chronic Cough Reduction in 24h cough frequency • 1-5% of the global population suffers from refractory 35 and/or unexplained chronic cough (RUCC) Mean relative change in 24-hour cough frequency vs placeb
Slide 21: Expanding the Clinical Program for Eliapixant
6 P2X3 Rec. Antagonist Expanding the Clinical Program for Eliapixant Overactive Bladder (OAB) Endometriosis Neuropathic Pain • Characterized by urinary • Characterized by the presence of • Neuropathic pain is due to urgency endometrium-like cells growing lesions of the central or outside of the uter
Slide 22: R&D Focus Areas in Oncology
7 Oncology R&D Focus Areas in Oncology Precision Molecular Targeted Alpha Immuno- Oncology Therapies Oncology • Exploiting intracellular • Tumor targeting Th-227 • Focused on select next- oncogenic dependencies conjugates unique to generation immuno- with SMOLs & new Bayer oncology targets modalitie
Slide 23: Addressing High Unmet Need of EGFRexon20 Cancer Patients With A Novel Small Molecule Kinase Inhibitor
7 Oncology Addressing High Unmet Need of EGFRexon20 Cancer Patients With A Novel, Potent and Selective Small Molecule Kinase Inhibitor EGFR Exon20ins in NSCLC High unmet medical need Preclinical anti-tumor efficacy EGFRexon 20 mouse tumor model • EGFR clinical validated target; EGFR exon-20 insertio
Slide 24: Bayer's ATR Inhibitor Demonstrates Preclinical Activity as a Single Agent and in Combination
7 Oncology Bayer’s ATR Inhibitor Demonstrates Preclinical Activity as a Single Agent and in Combination with PD-1 and PARPi Single Agent Model With PD-1 With PARPi Control Control Control ATRi ATRi+Anti-PD-1 ATRi+PARPi Tumor v olume (mm3, mean±SEM) • Tumor cells – not normal cells - are often relian
Slide 25: We are Pursuing Targeted Alpha Therapies with Potential Across Multiple Tumors
7 Oncology We are Pursuing Targeted Alpha Therapies with Potential Across Multiple Tumors Xofigo vs. Antibody-Targeted Therapies Systemic Prostate treatment Cancer targeting cancer Immune-Inflamed Launched: Xofigo (Ra-223) (bone) cells in the bone Broader Systemic treatment to target sites of Pipeli
Slide 26: Pioneering Off the Shelf, Allogeneic T-Cell Immunotherapies with Atara Biotherapeutics
7 Oncology Pioneering Off the Shelf, Allogeneic T-Cell Immunotherapies with Atara Biotherapeutics Autologous Allogeneic • Collaboration with Atara on next-generation, CAR-T technology CAR-T technology mesothelin-directed CAR T-cell therapies for the treatment of solid tumors • Leveraging Atara´s lea
Slide 27: Key Priorities for New R&D Leadership to Drive Transformation of our Innovation Model at Pharma
8 Priorities Key Priorities for New R&D Leadership to Drive Transformation of our Innovation Model at Pharma 1 Focus, advance and enhance Bayer’s pipeline to deliver innovation to patients 2 Use momentum of BlueRock, AskBio and CureVac to accelerate R&D processes 3 Strategic re-allocation of resourc
Slide 28: Paving the Way for our Future in Science-based Innovation
Paving the Way for our Future in Science-based Innovation /////////// Capital Markets Day March 10-11, 2021 Christian Rommel Head of R&D Pharmaceuticals 28
Slide 29: Appendix 1: R&D Pipeline Overview (as of Feb. 2020)
Appendix 1: R&D Pipeline Overview (as of Feb. 2020) 29 /// Bay er Capital Markets Day 2021 /// Paving the Way for our Future in Science-based Innovation /// March 10-11, 2021
Slide 30: Appendix 2: Abbreviations
Appendix 2: Abbreviations AAV Adeno-associated virus FXa Factor Xa AE Adverse event FXI / FXIa Factor XI / Factor XIa AR Androgen receptor HF Heart failure ATR Ataxia telangiectasia and Rad3-related protein HFrEF Heart failure with reduced ejection fraction ATRi Ataxia telangiectasia and Rad3-relate
Slide 31: Appendix 2: Abbreviations
Appendix 2: Abbreviations NTRK Neurotrophic Tyrosine Kinase T2D Type 2 diabetes mellitus NOAC New oral anticoagulant VKA Vitamin K antagonists OAB Overactive bladder VMS Vasomotor symptoms od Once daily VTE Venous thromboembolism PARPi Poly (Adenosine diphosphate (ADP)-ribose) polymerase inhibitors